The META-AF trial found fewer recurrences of atrial arrhythmias, a benefit unexplained by weight loss or glycemic control.

The PFA-SHAM trial and MANIFEST-US registry support the efficacy and safety of the increasingly used ablation modality.

EchoPrime was trained on more than 12 million videos; it’s now being tested clinically, with more data expected next year.

The drug, delivered by EMS as a single injection, improved infarct-related patency at cath lab arrival and 30-day clinical ...

The answer is very clear that if you have MI and preserved EF, there is no benefit of using a beta-blocker. Sripal Bangalore ...

The hope is using AI to judge outcomes will ease the high cost and complexity of running big clinical trials, say researchers ...

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...

The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.

NEW ORLEANS, LA—Sodium-glucose cotransporter 2 (SGLT2) inhibition does not seem to be a solution to the problem of arrhythmia ...

In TUXEDO-2, ticagrelor failed to meet the bar for noninferiority, with most outcomes hinting at an advantage for prasugrel.

The drug, given as a weekly subcutaneous injection, reduced both triglycerides and liver fat in the phase II trial.

There was an increase in the hepatic fat fraction, the long-term consequences of which are unknown, says Robert Rosenson.